🔎 Trials Near Me

Home › Eosinophilic Esophagitis › NCT06817213

Patient-Centered Decision Support for Eosinophilic Esophagitis

Recruiting

Patient-Centered Decision Support for Eosinophilic Esophagitis: A Pilot Study

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* New EoE patient evaluations ≥18 years old at University of Michigan (UM) that have an upcoming outpatient visit in a UM-gastroenterology or allergy \& immunology clinic,
* Able to speak and read English.

Exclusion Criteria:

* Prisoners and institutionalized individuals due to logistical limitations for use of a web app and follow-up interactions in these populations.
* Patients that have significant cognitive or visual impairment that limits interaction with the decision aid (DA)
* Patients that are terminally ill
* Patients that do not have an email address or reliable access to the internet

About the study

The study team is conducting this project to learn more about how patients with eosinophilic esophagitis (EoE) like to use and receive educational materials about treatment options and treatment decision making.

This study will assess the efficacy of a decision support intervention to make decisions about treatment and disease management for patients with EoE and will assess the feasibility and acceptability of the intervention to inform future R01-level studies.

The study team hypothesize that deploying the intervention will be feasible, and it will demonstrate high acceptability among EoE patients. Additionally, that patients that use the intervention (vs general education about EoE) will report greater treatment knowledge, increased readiness to choose a therapy, adherence to therapy, and follow-up.

What is being tested

Sponsor: University of Michigan · Participants: 40 · Started: Apr 16, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06817213

Locations in the U.S.

MichiganUniversity of Michigan, Ann Arbor

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.